DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Why DexCom (DXCM) Could Beat Earnings Estimates Again
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
by Riya Anand
Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCG
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Cooper Companies' (COO) Buyout to Boost Women's Healthcare
by Zacks Equity Research
Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.
Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
Earnings Estimates Rising for DexCom (DXCM): Will It Gain?
by Zacks Equity Research
DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Company News for Nov 1, 2021
by Zacks Equity Research
Companies In The News Are: DXCM, RSG, ABBV, CVX.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 43.55% and 6.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Is a Surprise Coming for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil
Catalent (CTLT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.
5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week
by Nalak Das
Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.
Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.